AstraZeneca has licensed in an antisense drug from Ionis Pharmaceuticals to treat kidney disease in a deal worth up to $330 million. Antisense drugs contain non-coding strands of mRNA that block ...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

It's been around six months since I last updated on Ionis Pharmaceuticals (NASDAQ:IONS), the Carlsbad, California-based developer of antisense, oligonucleotide therapeutic drugs. In my last note ...

Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. While preparing to go head to head in a rare disease market, the companies have signed up ...

In December 2019, Biogen exercised a license option with Ionis Pharmaceuticals and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080 (tau ASO).

CARLSBAD, Calif., April 16, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30 th at 11:30 a.m. Eastern Time ...

H.C. Wainwright initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $45 price target Ionis is a commercial-stage biotech company focused on RNA-targeted therapeutics for a ...

The market expects Ionis Pharmaceuticals (IONS) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30 th at 11:30 a.m. Eastern Time to discuss its first quarter 2025 financial results.